REGENXBIO, founded in 2009, is a clinical-stage biotechnology company that pioneers adeno-associated virus (AAV) gene therapy. It focuses on developing curative treatments for serious diseases through its advanced genetic platform.
The company's technical expertise is centered on Gene Therapy and AAV Vector Technology. Its pipeline includes investigational treatments such as RGX-202 for Duchenne Muscular Dystrophy, reflecting a focus on addressing unmet medical needs.
REGENXBIO operates with a patient-centric approach and core values of Trust, Accountability, Perseverance, and Innovation. This environment supports its work in a field that combines scientific research with technological innovation.
